RSNA 2025: Page 8

ChatGPT is fast, accurate for ICD-10 coding of PET/CT exams
By Erik L. Ridley
In this presentation, attendees will learn how ChatGPT can assist radiologists with proper ICD-10 coding of PET/CT exams.
November 20, 2025
Group explores DL MRI reconstruction as a 'green pathway'
By Liz Carey
AI-powered MRI offers a "green pathway" for routine clinical workflows, according to details of this Wednesday morning session.
November 20, 2025
AI image reconstruction in MRI satisfies radiologists and patients
By Erik L. Ridley
Not only does AI-based MRI reconstruction enhance image quality and diagnostic confidence, but patients like it too.
November 20, 2025
Mayo trains modified BigBird model for autoprotocoling
By Liz Carey
This session will provide a performance report for two different models for automatically generating protocols for imaging studies.
November 20, 2025
Generative AI-assisted CT reads cut reporting time
By Liz Carey
In a live clinical setting application, generative AI increased reporting efficiency for CT studies by nearly one-fourth.
November 20, 2025
Road to RSNA 2025: Molecular Imaging Preview
By Will Morton
The green flag is up, and nuclear medicine and molecular imaging have plenty of fuel in their tank on the 2025 Road to RSNA.
November 19, 2025
Road To Rsna
Additional Coverage
2024
2023
2022
2021
2020
2019
Different breast cancer treatments lead to varied effects on heart health
By Amerigo Allegretto
Session attendees will learn how different chemotherapy regimens affect myocardial accumulation in breast cancer patients.
November 19, 2025
Pentixafor PET/CT promising in patients with primary aldosteronism
By Will Morton
Ga-68 pentixafor PET/CT shows high accuracy in detecting aldosterone-producing adenomas in patients with primary aldosteronism.
November 19, 2025
New tracer may guide surgery in patients with PHPT
By Will Morton
PET/CT imaging with the radiotracer gallium-68 trivehexin offers high sensitivity for detecting hyperfunctioning parathyroid tissue.
November 19, 2025
PET identifies risk of adverse events in Lu-177 PSMA treatment
By Will Morton
Bone tumor volume is associated with adverse events in prostate cancer patients who received Lu-177 PSMA treatment, presenters say.
November 19, 2025
SPECT/CT predicts response to Lu-177 PSMA-617 treatment
By Will Morton
Lu-177 PSMA-617 benefits patients with metastatic castration-resistant prostate cancer, but individual outcomes vary.
November 19, 2025
PET identifies reduced brain activity in ALS patients
By Will Morton
F-18 FDG-PET/CT scans have linked reduced brain metabolism and survival in patients with amyotrophic lateral sclerosis (ALS).
November 19, 2025
Previous Page
Page 8 of 15
Next Page